SAN DIEGO (AP) — SAN DIEGO (AP) — Travere Therapeutics, Inc. (TVTX) on Monday reported a loss of $52.3 million in its third ...
Investor's Business Daily on MSN
Travere is on a crash course with its 200-day line — here's what happened
Shares of Travere Therapeutics took a hit Tuesday, but closed in the green, after fewer than expected patients started taking ...
Travere Therapeutics (NASDAQ:TVTX) reported third-quarter results marked by record FILSPARI sales, continued early adoption in focal segmental glomerulosclerosis (FSGS), and progress across its kidney ...
Q3 earnings swing to loss as revenue rises Travere Therapeutics (TVTX) just delivered third quarter 2026 numbers that pulled investor attention to both sides of the income statement. Revenue reached ...
Management reiterated the long-term FILSPARI goal rather than issuing quarterly EPS or revenue guidance: Dr. Dube said results and demand trends “are aligned with our long-term goals of achieving $3 ...
U.S. net product sales for the third quarter of 2026 were $220.2 million, compared to $113.2 million for the same period in ...
Revenue went the other way. It reached $224.56 million, beating the $192.52 million consensus by 16.6% and growing 36.2% year over year. FILSPARI net sales crossed $200 million for the first time, ...
Travere Therapeutics stock falls 2.2% to $49.26 today after the latest financial results and leadership update.
Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that company management will participate in the following upcoming investor conferences: Guggenheim Global Healthcare Conference Presenting on ...
Travere Therapeutics has delivered a very large 3 year share price gain, which naturally puts the spotlight on whether the ...
Reports Q3 revenue $224.6M, consensus $195.3M. “Strong execution across our business drove another quarter of significant ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results